About us

Our mission is to democratize healthcare testing to positively impact human health through actionable data.

Meet us

We look forward to connecting via LinkedIn.
Dr. Hong Cai
Co-Founder & CTO
view bio

Dr. Hong Cai co-founded the business in 2009. She has more than 20 years of experience in the field of molecular biology and is the inventor of the technology used in Mesa Biotech’s platform. She spent 13 years as a principal investigator at Los Alamos National Laboratory, managing and leading projects for nucleic acid-based assays for forensic analysis, biothreat pathogen detection, and human disease diagnosis.

Dr. Bruce Cary
Co-Founder & CSO
view bio

Dr. Cary is a co-founder of Mesa Biotech and the inventor of the technology that is the basis of the company’s platform. As CSO, he leads projects for the development of rapid molecular tests. Previously he spent 13 years as a principal investigator and scientist at Los Alamos National Laboratory, leading projects focused on biodefense, pathogen detection, nucleic acid metabolism and microarray gene expression technology.

Ingo Chakravarty
President & Chief Executive Officer
view bio

Ingo Chakravarty has led expansive growth in several diagnostic/genomic companies. He has over 25 years of experience and a proven track record in capital formation and building, and leading high performing organizations in healthcare that create differentiated solutions to outperform in the marketplace and generate sustainable, long term growth. He most recently served as President and CEO of NAVICAN Genomics and previously spent two decades building global businesses in the oncology and infectious disease marketplace, holding senior leadership positions at GenMark Diagnostics, Gen-Probe, Roche and Ventana Medical Systems.

Daniel De La Vega
SVP Operations
view bio

Dan de la Vega has led site operations though significant change related to acquisitions/divestitures, process scale-up, and facility transfers at several point-of-care diagnostics companies. He has over 30 years of experience in cGMP manufacturing and Operational Strategy. For the last two decades, he has focused on delivering financial results, quality products, and efficient processes in the rapid diagnostics industry and has held increasingly senior leadership positions at Alere, Abbott, and B. Braun Medical. He leads Site Operations for Mesa Biotech.

Kyla Hayden, JD
Chief People Officer
view bio

Kyla brings game-changing strategic leadership to facilitate and support sustainable growth. She scaled CrossFit’s significant labor growth from 800-15,000 units while maintaining culture and developing talent. She brings analytical rigor to the people function and has built and tracked ROI metrics that are driven by and align with the needs of the business. Her experience as a practicing attorney has brought a more analytical approach to the people function.

Kyla is known for cultivating an environment with a strong sense of community supported by a growth mindset. She encourages her team to use their talents, grow from their mistakes, and models accountability and responsibility. She constantly pushes them to grow, knowing that many tasks are hard before they become easy. Her leadership style is one that is tailored and built upon the most powerful attribute—trust.

Mark Ibison
Chief Financial Officer
view bio

Mark Ibison has over 20 years of experience across the full breadth of finance and accounting, supporting commercial teams to drive growth, manufacturing teams to improve profitability and as a strategic partner to general managers. He has also had operational responsibilities, managing procurement, distribution and continuous improvement functions.

He was most recently CFO at Prescient Medicine, an early-stage diagnostics company where he led fundraising efforts while building the accounting/finance function from the ground up. Prior to Prescient Medicine, Mark spent 6 years at Thermo Fisher where he was the Divisional CFO for businesses in the Life Sciences and Specialty Diagnostics groups. Earlier in his career, Mark held a number of finance leadership roles at Essentra, a UK-based FTSE 250 B2B manufacturer and distributor.

Julie Richardson
VP Quality and Regulatory Affairs
view bio

Julie Richardson leads the commitment to superior Quality Systems for Mesa Biotech with 20+ years of IVD, Clinical, and Pharma experience in the areas of Development, Manufacturing Technical Support, Validation, and Quality Systems. She held positions of increasing responsibilities at companies such as Hybritech, Gen-Probe, and Teva Pharmaceuticals.

Don Thomas
VP Engineering and Product Development
view bio

Don Thomas leverages 25+ years of experience in Product Development to lead Mesa Biotech engineering and R&D efforts. He has a successful track record leading cross-disciplinary teams in development of both molecular and cell-based assay systems. Previously, he held senior leadership positions at ACEA Biosciences and Nanogen.

Dr. Hong Cai
Co-Founder & CTO
view bio

Dr. Hong Cai co-founded the business in 2009. She has more than 20 years of experience in the field of molecular biology and is the inventor of the technology used in Mesa Biotech’s platform. She spent 13 years as a principal investigator at Los Alamos National Laboratory, managing and leading projects for nucleic acid-based assays for forensic analysis, biothreat pathogen detection, and human disease diagnosis.

Ingo Chakravarty
President & Chief Executive Officer
view bio

Ingo Chakravarty has led expansive growth in several diagnostic/genomic companies. He has over 25 years of experience and a proven track record in capital formation and building, and leading high performing organizations in healthcare that create differentiated solutions to outperform in the marketplace and generate sustainable, long term growth. He most recently served as President and CEO of NAVICAN Genomics and previously spent two decades building global businesses in the oncology and infectious disease marketplace, holding senior leadership positions at GenMark Diagnostics, Gen-Probe, Roche and Ventana Medical Systems.

Kyla Hayden, JD
Chief People Officer
view bio

Kyla brings game-changing strategic leadership to facilitate and support sustainable growth. She scaled CrossFit’s significant labor growth from 800-15,000 units while maintaining culture and developing talent. She brings analytical rigor to the people function and has built and tracked ROI metrics that are driven by and align with the needs of the business. Her experience as a practicing attorney has brought a more analytical approach to the people function.

Kyla is known for cultivating an environment with a strong sense of community supported by a growth mindset. She encourages her team to use their talents, grow from their mistakes, and models accountability and responsibility. She constantly pushes them to grow, knowing that many tasks are hard before they become easy. Her leadership style is one that is tailored and built upon the most powerful attribute—trust.

Julie Richardson
VP Quality and Regulatory Affairs
view bio

Julie Richardson leads the commitment to superior Quality Systems for Mesa Biotech with 20+ years of IVD, Clinical, and Pharma experience in the areas of Development, Manufacturing Technical Support, Validation, and Quality Systems. She held positions of increasing responsibilities at companies such as Hybritech, Gen-Probe, and Teva Pharmaceuticals.

Dr. Bruce Cary
Co-Founder & CSO
view bio

Dr. Cary is a co-founder of Mesa Biotech and the inventor of the technology that is the basis of the company’s platform. As CSO, he leads projects for the development of rapid molecular tests. Previously he spent 13 years as a principal investigator and scientist at Los Alamos National Laboratory, leading projects focused on biodefense, pathogen detection, nucleic acid metabolism and microarray gene expression technology.

Daniel De La Vega
SVP Operations
view bio

Dan de la Vega has led site operations though significant change related to acquisitions/divestitures, process scale-up, and facility transfers at several point-of-care diagnostics companies. He has over 30 years of experience in cGMP manufacturing and Operational Strategy. For the last two decades, he has focused on delivering financial results, quality products, and efficient processes in the rapid diagnostics industry and has held increasingly senior leadership positions at Alere, Abbott, and B. Braun Medical. He leads Site Operations for Mesa Biotech.

Mark Ibison
Chief Financial Officer
view bio

Mark Ibison has over 20 years of experience across the full breadth of finance and accounting, supporting commercial teams to drive growth, manufacturing teams to improve profitability and as a strategic partner to general managers. He has also had operational responsibilities, managing procurement, distribution and continuous improvement functions.

He was most recently CFO at Prescient Medicine, an early-stage diagnostics company where he led fundraising efforts while building the accounting/finance function from the ground up. Prior to Prescient Medicine, Mark spent 6 years at Thermo Fisher where he was the Divisional CFO for businesses in the Life Sciences and Specialty Diagnostics groups. Earlier in his career, Mark held a number of finance leadership roles at Essentra, a UK-based FTSE 250 B2B manufacturer and distributor.

Don Thomas
VP Engineering and Product Development
view bio

Don Thomas leverages 25+ years of experience in Product Development to lead Mesa Biotech engineering and R&D efforts. He has a successful track record leading cross-disciplinary teams in development of both molecular and cell-based assay systems. Previously, he held senior leadership positions at ACEA Biosciences and Nanogen.

Read more about us

Press releases
Apr 14, 2020 Mesa Biotech announces Ingo Chakravarty as president and CEO
Read More
Apr 14, 2020 Mesa Biotech to ship 10,000 accula SARS-CoV-2 tests this week for 30 minute rapid molecular point of care diagnosis
Read More
Mar 24, 2020 Mesa Biotech receives emergency use authorization from FDA for a 30 minute point of care molecular COVID-19 test
Read More
Mar 19, 2020 Mesa Biotech to receive funding from US health and human services for development of a 30 minute molecular (PCR) point-of-care SARS-CoV-2 test
Read More
Mar 4, 2020 Mesa Biotech developing molecular point-of-care (PCR) diagnostic test for novel coronavirus (COVID-19)
Read More
Jul 31, 2019 Mesa Biotech to present comparative flu & RSV detection analysis with other FDA-cleared molecular assays at the AACC annual scientific meeting lecture series
Read More
Jul 29, 2019 Mesa Biotech to launch molecular, sample-to-answer RSV test at the 2019 AACC annual scientific meeting
Read More
Apr 9, 2019 Mesa Biotech to introduce expanded molecular POC testing portfolio at the European Congress of Clinical Microbiology and Infectious Diseases
Read More
Mar 19, 2019 Mesa Biotech named 2019 frost & sullivan price/performance value leaderin global influenza point-of-care testing
Read More
Media coverage
Mar 20, 2019 Mesa Biotech wins the Frost & Sullivan Price/Performance Value Leadership Award
Read More
Jun 29, 2016 Mesa Biotech Appoints Leading TriCore Reference Laboratory Expert to Inaugural Scientific Advisory Board (Tricore.org)
Read More
May 23, 2016 Point-of-Care Flu MDx from Mesa Biotech May Head to FDA Next Year (GenomeWeb.com)
Read More
Apr 6, 2016 Retired Salk Institute President joins San Diego’s Mesa Biotech (San Diego Union-Tribune)
Read More
Jun 12, 2014 Mesa Tech Wins $1M Phase II SBIR Award to Continue Developing POC Respiratory Pathogen Test (GenomeWeb.com)
Read More
Apr 3, 2012 Inexpensive handheld tests for diseases are in sight (Los Alamos National Laboratory)
Read More
Apr 18, 2011 LANL Spinout Mesa Tech Wins SBIR Grant for Disposable POC Nucleic Acid Testing Device (GenomeWeb.com)
Read More

Join us

Pardon our dust! We are under construction and growing fast. We are excited to make your acquaintance and connect further.

If you like the start-up environment, have a problem-solving mindset, want autonomy working for an innovative company; get ready to roll-up your sleeves and join our team of collaborative people.

Send your resume to [email protected]

 

Amazing things are happening here!

– First company funded through 2 phases under the NIH Rapid Acceleration of Diagnostics program

– Expanding footprint and scale-up cGMP manufacturing of COVID–19 PCR rapid tests

– Currently building a dynamic and experienced scale-up team

– Projecting 200+ positions in Q4, 2020

Contact us

Address: San Diego, CA
Phone: 858-800-4929
Emails: [email protected]